A new bis-pyrazolylpyridine ruthenium(iii) complex as a potential anticancer drug: in vitro and in vivo activity in murine colon cancer-Reference-Cited by-同舟云学术

A new bis-pyrazolylpyridine ruthenium(iii) complex as a potential anticancer drug: in vitro and in vivo activity in murine colon cancer

Published:2021 Issue:22 Volume:50 Page:7686-7704
ISSN:1477-9226
Container-title:Dalton Transactions
language:en
Short-container-title:Dalton Trans.

Author:

Lazić Dejan¹²³⁴⁵,Scheurer Andreas⁶⁷⁸⁹¹⁰^ORCID,Ćoćić Dušan¹¹¹²⁴⁵^ORCID,Milovanović Jelena¹³²¹¹¹⁴⁵,Arsenijević Aleksandar¹³²¹¹¹⁴⁵,Stojanović Bojana¹³²¹¹¹⁴⁵,Arsenijević Nebojša¹³²¹¹¹⁴⁵,Milovanović Marija¹³²¹¹¹⁴⁵,Rilak Simović Ana¹¹¹⁵¹⁶⁴⁵^ORCID

Affiliation:

1. Department of Surgery

2. Faculty of Medical Sciences

3. University of Kraujevac

4. 34000 Kragujevac

5. Serbia

6. Inorganic Chemistry

7. Department of Chemistry and Pharmacy

8. University of Erlangen-Nürnberg

9. Erlangen

10. Germany

11. University of Kragujevac

12. Faculty of Science

13. Center for Molecular Medicine and Stem Cell Research

14. Kragujevac

15. Institute for Information Technologies Kragujevac

16. Department of Natural Sciences

Abstract

Ru pincer-type complex 1 reduced primary tumor growth and the number and growth of lung and liver metastases, significantly prolonging the survival rate of treated mice.

Funder

Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja

Fakultet Medicinskih Nauka, Univerziteta U Kragujevcu

Publisher

Royal Society of Chemistry (RSC)

Subject

Inorganic Chemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2021/DT/D1DT00185J

Reference97 articles.

1. Multicenter Phase II Study of Bimonthly High-Dose Leucovorin, Fluorouracil Infusion, and Oxaliplatin for Metastatic Colorectal Cancer Resistant to the Same Leucovorin and Fluorouracil Regimen

2. Oxaliplatin-safety profile: neurotoxicity